Logo Image

Video Shorts

Don't Ignore the Signs: Why Increased Awareness of Early Endometrial Cancer Symptoms Is Critical
0:53
Don't Ignore the Signs: Why Increased Awareness of Early Endometrial Cancer Symptoms Is Critical
a year ago
by
Dana Chase, MD
Is Early Mortality Associated With Real-World Bispecific Antibody Use in R/R Multiple Myeloma?
0:45
Is Early Mortality Associated With Real-World Bispecific Antibody Use in R/R Multiple Myeloma?
a year ago
by
Carlyn Rose Tan, MD
Jonathan H. Sherman, MD, FAANS, FCNS, FACS, Rutgers Cancer Institute
0:37
Unpacking Advances in the Surgical Management of Brain Cancer
a year ago
by
Jonathan H. Sherman, MD, FAANS, FCNS, FACS
Ryan M. Kahn, MD, MHS, FACOG, of Baptist Health Miami Cancer Institute
1:01
Ongoing Challenges With Surgery in Ovarian Cancer
a year ago
by
Ryan M. Khan, MD, MHS, FACOG
Michelle Monje, MD, PhD, of Stanford University
0:44
Using CAR T-Cell Therapy in Diffuse Midline Gliomas
a year ago
by
Michelle Monje, MD, PhD
John P. Diaz, MD, of Baptist Health
0:34
The Role of Minimally Invasive Surgery in Uterine Cancer
a year ago
by
John Paul Diaz, MD
Real-World Outcomes of Patients With Newly Diagnosed Multiple Myeloma Treated with Front-Line DRd
1:26
Real-World Outcomes of Patients With Newly Diagnosed Multiple Myeloma Treated with Front-Line DRd
a year ago
by
Ricardo D. Parrondo, MD
Maurie Markman, MD
1:24
Landmark Trials in Advanced Ovarian Cancer
a year ago
by
Maurie Markman, MD
2025 IMS Annual Meeting: Experts Recap Latest Advances in Multiple Myeloma
2:17
2025 IMS Annual Meeting: Experts Recap Latest Advances in Multiple Myeloma
a year ago
by
Ashling Wahner
Ken Culver, MD, and D. Ross Camidge, MD, PhD
2:29
Managing Strategic and Patient Expectations in R&D
a year ago
by
Ross Camidge, MD, PhD(+1 more)
Adam Lee, and D. Ross Camidge, MD, PhD
1:58
Are Health Economists Promotional?
a year ago
by
Ross Camidge, MD, PhD(+1 more)
Brandon Blue, MD, and D. Ross Camidge, MD, PhD
2:38
How I Became a Healer
a year ago
by
Ross Camidge, MD, PhD(+1 more)
Heather McArthur, MD, UT Southwestern Medical Center
0:25
Sac-TMT Plus Pembrolizumab in TNBC
a year ago
by
Heather McArthur, MD, MPH
Eric K. Singhi, MD, of MD Anderson Cancer Center
0:43
Recapping the IASLC 2025 World Conference on Lung Cancer
a year ago
by
Eric K. Singhi, MD
Mack Roach III, MD
0:34
How AI Is Reshaping Cancer Care
a year ago
by
Mack Roach III, MD
Joel Neal, MD, PhD
1:00
DNA- and RNA-Based Sequencing in Lung Cancer
a year ago
by
Joel Neal, MD, PhD
Beau Webber, PhD
2:08
CISH Knockout TIL Therapy Using CRISPR Editing to Enhance T-Cell Function in GI Cancers
a year ago
by
Beau Webber, PhD
The Evolving Treatment Paradigm for Leukemia and Lymphoma
1:04
The Evolving Treatment Paradigm for Leukemia and Lymphoma
a year ago
by
Jorge Cortes, MD
The Importance of Early Recognition for Optimal Uterine Cancer Management
0:45
The Importance of Early Recognition for Optimal Uterine Cancer Management
a year ago
by
John Paul Diaz, MD
Sara M. Tolaney, MD, MPH, of Dana-Farber Cancer Institue
0:44
Rationale for Combining Sac-TMT With Pembrolizumab in HR+, HER2– Breast Cancer
a year ago
by
Sara M. Tolaney, MD, MPH
Narjust Florez, MD
0:41
The Importance of a Consensus Manuscript to Bridge Gaps in Lung Cancer
a year ago
by
Narjust Florez, MD
Paul Gellhaus, MD, discusses the importance of accurate diagnosis and effective management strategies to kick off Prostate Cancer Awareness Month
0:38
Common Disease, Critical Choices: Navigating Prostate Cancer Management
a year ago
by
Paul Gellhaus, MD
Christine Ann Garcia, MD, MPH
0:34
Challenges in Transitioning to Research for Hematology/Oncology Fellows
a year ago
by
Christine Ann Garcia, MD, MPH
Ashish Saxena, MD, PhD
0:40
Advice for Hematology/Oncology Fellows for Handling a New Cancer Diagnosis
a year ago
by
Ashish Saxena, MD, PhD
Fawzi F Abu Rous, MD, discusses the investigation of the PD-L1 and VEGF-targeted bispecific antibody ivonescimab in NSCLC.
0:34
Ongoing Development of Ivonescimab in NSCLC
a year ago
by
Fawzi F Abu Rous, MD
Geoffrey B. Pelz, MD
0:59
Minimally Invasive Surgery Should Be Carefully Explained to Patients With Lung Cancer
a year ago
by
Geoffrey B. Pelz, MD
Nisha Joseph, MD, and Hans Lee, MD, discuss the clinical significance of the FDA's approval of linvoseltamab for relapsed/refractory multiple myeloma.
1:24
FDA Approval of Linvoseltamab for Relapsed/Refractory Multiple Myeloma
a year ago
by
Nisha Joseph, MD(+1 more)
Connie Lai, MD, discusses a retrospective analysis comparing the use of post-induction treatment strategies for patients with metastatic colorectal cancer.
1:07
Retrospective Analysis of Post-Induction Treatment Strategies in mCRC
a year ago
by
Connie Lai, MD
Ignacio Blanco, MD, PhD, discusses the clinical significance of the EU approval of mirdametinib for NF1-associated neurofibromas.
0:43
EU Approval of Mirdametinib for NF1-Associated PNs
a year ago
by
Ignacio Blanco, MD, PhD
Breelyn Wilky, MD, discusses the prevalence of KIT mutations and development of treatment resistance in gastrointestinal stromal tumors.
0:38
KIT Mutations and Treatment Resistance in GIST: What You Need to Know
a year ago
by
Breelyn A. Wilky, MD